Class / Patent application number | Description | Number of patent applications / Date published |
514190800 | Metastasis affecting | 28 |
20100286064 | POLYPEPTIDE INHIBITING TRANSMIGRATION OF LEUKOCYTES OR GROWTH AND/OR METASTASIS OF CANCER CELLS, AND FUSION PROTEIN THEREOF - The present invention provides a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, or a fusion protein thereof. The present invention also provides a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases including the polypeptide or a fusion protein thereof. The present invention also provides a pharmaceutical composition for inhibiting the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof. | 11-11-2010 |
20100298234 | Cancer therapeutic agents comprising a ligand for the neuromedin u receptor 2 (fm4) molecule as an active ingredient - The present inventors discovered that the neuromedin U receptor 2 (FM4) molecule is highly expressed in cancer cells such as pancreatic cancer cells. When the present inventors measured the proliferation-suppressing effect of ligands of this molecule against cancer cells, the ligands were found to have cancer cell proliferation-suppressing effects. The present inventors also discovered that this effect was produced by an FM4 molecule-mediated signal. These findings showed that ligands for the neuromedin U receptor 2 (FM4) molecule are effective for the treatment of cancers with enhanced expression of the neuromedin U receptor 2 (FM4) molecule, including pancreatic cancer, as well as for prevention of metastasis. | 11-25-2010 |
20100305043 | CCL18 AND CCL3 METHODS AND COMPOSITIONS FOR DETECTING AND TREATING CANCER - The invention relates to methods of treating cancer by administering one or more chemokines that are downregulated in cancerous cells. More specifically, the invention provides methods for treating or preventing cancers such as malignant melanoma by administering a chemokine such as CCL18 and/or CCL3. The invention further provides methods for diagnosing cancer such as melanoma. | 12-02-2010 |
20100323971 | CELL PERMEABLE NM23 RECOMBINANT PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME, AND ANTI-METASTATIC COMPOSITION COMPRISING THE SAME - The present invention discloses cell permeable Nm23 recombinant proteins where a macromolecule transduction domain (MTD) is fused to a metastasis suppressor Nm23. Also disclosed are polynucleotides encoding the cell permeable Nm23 recombinant proteins, an expression vector containing the cell permeable Nm23 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable Nm23 recombinant protein as an effective ingredient. The cell permeable Nm23 recombinant proteins of the present invention can induce KSR phosphorylation and inactivation and inhibit Ras-mediated MAPK cascade by efficiently introducing a metastasis suppressor Nm23 into a cell. Therefore, the cell permeable Nm23 recombinant proteins of the present invention can be effectively used as an anti-metastatic agent capable of preventing cancer metastasis by inhibiting the proliferation, differentiation and migration of cancer cells. | 12-23-2010 |
20110021442 | CELL PREAMBLE RUNX3 RECOMBINANT PROTEINS, POLYNUCLEOTIDES ENCODING THE SAME, AND ANTICANCER COMPOSITIONS INCLUDING THE SAME - The present invention discloses cell permeable RUNX3 recombinant proteins where a Macromolecule Transduction Domain (MTD) is fused to a tumor and metastasis suppressor RUNX3. Also disclosed are polynucleotides encoding the cell permeable RUNX3 recombinant proteins, an expression vector containing the cell permeable RUNX3 recombinant protein, and a pharmaceutical composition for preventing metastasis which contains the cell permeable RUNX3 recombinant protein as an effective ingredient. The cell permeable RUNX3 recombinant proteins of the present invention can induce the reactivation of TGF-β signal transduction pathway which causes cell cycle arrest by efficiently introducing a tumor and metastasis suppressor RUNX3 into a cell. Therefore, the cell permeable RUNX3 recombinant proteins of the present invention can be effectively used as an anticancer agent capable of preventing cancer growth and metastasis by suppressing the proliferation, differentiation, and migration of cancer cells. | 01-27-2011 |
20110144034 | INHIBITION OF TUMOR METASTASES USING PROTEIN KINASE C (PKC) INHIBITORS - Described are methods for reducing tumor metastasis in an animal by administering an inhibitor of a protein kinase C (PKC) isozyme. | 06-16-2011 |
20110224150 | METHODS FOR EFFECTING REGRESSION OF TUMOR MASS AND SIZE IN A METASTASIZED TUMOR - The present invention relates generally to methods of effecting regression of tumor size and mass of a metastasized tumor in a subject by administering an effective amount of a desulphatohirudin variant. | 09-15-2011 |
20110230423 | THERAPY AND MEDICAMENT USING INTEGRIN LIGANDS FOR TREATING CANCER - The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention. | 09-22-2011 |
20110263513 | Pharmaceutical Being Used For Treating Cancer and Fibrosis Disease and the Composition and Uses Thereof - Provided is the composition of a peptide and its mutagenic version, or other derivatives with the same 3-D structure with activity to bind the extracellular domain of PDGFR-α, or -β, but does not dimerize by itself, wherein said peptide comprises the sequence shown as SEQ ID NO: 1, 2 or 3. Also provided is the composition of the nucleotide sequence encoding said peptide and its derivatives, and the usage of said peptide and derivatives of the peptide in preparation of medicine for the prevention and treatment of fibrosis diseases, such as liver, kidney, and lung fibrosis, primary cancer, and cancer metastasis, especially stomach cancer, liver cancer, breast cancer, and lung cancer. | 10-27-2011 |
20110312899 | HDL Particles for Delivery of Nucleic Acids - Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are pharmaceutical compositions that include a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits. | 12-22-2011 |
20110319340 | METHODS FOR TREATING CANCER - The present invention includes methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a non-proteolytically activated thrombin receptor agonist. | 12-29-2011 |
20120015889 | METHOD FOR THE ADMINISTRATION OF LIGANDS, AGONISTS OF LIGANDS OF THE TNF FAMILY WITH REDUCED TOXICITY - The present invention concerns the use of a multimerized form of ligands of the TNF family for the preparation of a medicament for injection into an appropriate cavity of the body, for the treatment of diseases wherein cell proliferation has to be controlled wherein the ligand of the TNF family is selected among Fas ligand, CD40L, TRAIL and APRIL. | 01-19-2012 |
20120022000 | USE OF A PEPTIDE IN THE TREATMENT OR PREVENTION OF METASTASIS - The present invention relates to a peptide useful for the preparation of a medicament for the treatment or prevention of metastasis. Furthermore, it relates to a method of treatment or prevention of metastasis comprising administering to a subject in need thereof, a therapeutically effective amount of the peptide of the invention. | 01-26-2012 |
20120122798 | TREATMENT OF OVARIAN CANCER USING AN ANTICANCER AGENT CONJUGATED TO AN ANGIOPEP-2 ANALOG - Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an ammo acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2. | 05-17-2012 |
20130012451 | COMPOSITIONS AND METHODS FOR INHIBITING MMP-9-MEDIATED CELL MIGRATION - The invention provides peptides, portions and derivatives thereof, that are useful for reducing cell migration, and for reducing symptoms of pathological diseases that are associated with undersirable cell migration, and in particular MMP-9-induced cell migration. | 01-10-2013 |
20130012452 | METHOD FOR TREATING BRAIN CANCER USING A NOVEL TUMOR SUPPRESSOR GENE AND SECRETED FACTOR - The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers. | 01-10-2013 |
20130035295 | Use of Peptide Epoxyketones for Metastasis Suppression - The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics | 02-07-2013 |
20130045925 | COMPOSITIONS FOR AMELIORATING CELL PROLIFERATIVE DISORDERS AND METHODS OF MAKING AND USING THEM - In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG. | 02-21-2013 |
20130123192 | COMPOSITIONS AND METHODS FOR INHIBITING MATRIX METALLOPROTEINASE (MMP)-MEDIATED CELL MIGRATION - The invention provides peptides, portions and derivatives thereof, that are useful for reducing cell migration, and for reducing symptoms of pathological diseases that are associated with undesirable cell migration, and in particular MMP-induced cell migration. This invention also provides peptides that are useful for detecting (e.g., imaging) cancers. | 05-16-2013 |
20130296253 | Uses of an Immunomodulatory Protein (GMI) from Ganoderma Microsporum - The invention provides a method for inhibiting EGF receptor activity comprising contacting an | 11-07-2013 |
20140038901 | CIRCULATING EXOSOMES AS DIAGNOSTIC/PROGNOSTIC INDICATORS AND THERAPEUTIC TARGETS OF MELANOMA AND OTHER CANCERS - The present invention is directed to methods of diagnosing, preventing, and treating metastatic disease in a subject. The present invention is also directed to a method of inhibiting primary tumor growth in a subject. Methods of identifying candidate compounds useful for preventing and treating metastatic disease and primary tumor growth in a subject are also disclosed. | 02-06-2014 |
20140080764 | Drug Containing Recombinant Mistletoe Lectins for Treating Malignant Melanoma - The invention relates to a drug and/or pharmaceutical composition for treating metastatic tumors, in particular of malignant melanoma, above all of stage IV malignant melanoma, and to the use of said drug, in particular the use of said drug in select patient populations. | 03-20-2014 |
20140342995 | METHOD FOR TREATING BRAIN CANCER USING A NOVEL TUMOR SUPPRESSOR GENE AND SECRETED FACTOR - The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers. | 11-20-2014 |
20140364377 | USE OF PEPTIDE EPOXYKETONES FOR METASTASIS SUPPRESSION - The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics. | 12-11-2014 |
20160083734 | COMPOSITIONS AND METHODS FOR TREATING CANCER - A method of one or more of, inhibiting motility, migration, dispersal, and metastasis of a cell that expresses an RPTP, which is proteolytically cleaved to form intracellular fragments in the cell includes administering to the cell an amount of an agent effective to inhibit one or more of the catalytic activity and function of the proteolytically cleaved intracellular domain-containing fragments of the RPTP. | 03-24-2016 |
20160122391 | SHORT BETA-DEFENSIN-DERIVED PEPTIDES - The invention is directed to β-defensin-derived peptides and their use in modulating the activity of hematopoietic cells, particularly hematopoietic stem cells and progenitor cells. Specifically, the invention provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. The invention further provides compositions and methods useful in the treatment of cancer. | 05-05-2016 |
20160138113 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BRAIN METASTASIS - The present disclosure describes a method for determining metastasis-free survival of a subject with cancer based on the differential expression of genes that are associated with metastasis of the cancer to the brain, bone and/or lung. Detection of the expression level of these genes in a sample from the subject can identify an individual who is at risk for metastasis. | 05-19-2016 |
20160175391 | DRUG CONTAINING RECOMBINANT MISTLETOE LECTINS FOR TREATING MALIGNANT MELANOMA | 06-23-2016 |